NORKUNAS MATTHEW enters OBSIDIAN THERAPEUTICS, INC. with 30.94K shares plus derivative instruments
Holding both equity and derivatives at entry signals strong long-term conviction in the company.
Direct Derivatives
Filed: 8/3/2026ACC: 0001193125-26-330979
Director
Since Aug 2026
30.94K
Baseline shares
100% direct
30.94K
Direct ownership
1 position
231.56K
Derivative underlying
2 instruments
1
Security positions
All direct
Non-Derivative Holdings1
Common Stock
DirectShares owned30.94K
Total
30.94K direct30.94K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 30.94K | Direct |
| Total | 30.94K | 30.94K direct |
Derivative Holdings2
Stock Option (Right to Buy)
DirectUnderlying security
Common Stock
Underlying shares
51.56K
Shares owned
N/A
Exercise price
0.78
Expiration
—
Exercise window
—
Stock Option (Right to Buy)
DirectUnderlying security
Common Stock
Underlying shares
180K
Shares owned
N/A
Exercise price
0.78
Expiration
—
Exercise window
—
Total
Underlying
231.56K
Owned
0.00
| Security | Underlying | Exercise Price | Exercise Window | Expiration | Underlying Shares | Shares Owned |
|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock | 0.78 | — | — | 51.56K | N/A |
| Stock Option (Right to Buy) Direct | Common Stock | 0.78 | — | — | 180K | N/A |
| Total | 231.56K | 0.00 | ||||